Pfizer booster shot 95.6 pc effective against Covid-19


A booster shot of the BioNTech/Pfizer vaccine is 95.6% effective against Covid-19 compared with those receiving two shots and a placebo, the companies said.

They said a trial of 10,000 participants aged 16 or older showed 95.6% effectiveness against the diseases, during a period when the

strain was prevalent.

The study also found that the booster shot had a favourable safety profile.

Pfizer had said its two-shot vaccine’s efficacy drops over time, citing a study that showed 84% effectiveness from a peak of 96% four months after a second dose. Some countries had already gone ahead with plans to give booster doses.

In a tweet BioNTech said, “95.6% relative vaccine efficacy against #Covid19 after a booster shot with our #mRNA vaccine, during a period when Delta was the prevalent strain. These are the first efficacy results from any randomized, controlled vaccine booster trial.”

“These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease,” Pfizer CEO Albert Bourla said in a statement.

The median age of the participants was 53 years, with 55.5% of participants between 16 and 55 years, and 23.3% at 65 years or older.

(With inputs from Reuters)

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *